XenoPort, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 2.01%54.110.9%$2611.78m
JNJJohnson & Johnson 1.22%159.000.7%$1293.90m
MRKMerck & Co., Inc. -1.07%73.100.7%$1148.17m
BMYBristol-Myers Squibb Co. 2.00%56.521.0%$760.12m
LLYEli Lilly & Co. -0.98%245.441.1%$728.54m
ABBVAbbVie, Inc. 0.94%117.971.9%$587.47m
AZNAstraZeneca Plc -1.07%54.211.0%$290.18m
NVSNovartis AG -0.01%79.950.2%$176.56m
GSKGlaxoSmithKline Plc -0.41%41.300.2%$165.36m
DRNADicerna Pharmaceuticals, Inc. -0.11%38.080.3%$144.50m
VTRSViatris, Inc. 0.00%12.200.0%$141.37m
RPRXRoyalty Pharma Plc -2.68%37.840.1%$111.76m
RGENRepligen Corp. -2.78%261.366.7%$107.40m
BFRIBiofrontera, Inc. -20.38%4.180.0%$104.27m
PTPIPetros Pharmaceuticals, Inc. 5.37%2.730.0%$95.04m

Company Profile

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.